Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
US9951079B2 · kind B2 · utility
3Cited by
15References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2014 |
| Grant date | Apr 24, 2018 |
| Priority date | — |
| Expiry date | Sep 4, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, m, R1, R5, Ra and Rb are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.